Zydus to acquire Agenus’ US manufacturing facilities, forays into global biologics CDMO business

Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray

The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides

Bora Pharmaceuticals acquires Eden Biologics CDMO assets

Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market

We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships

Celonic and Carbogen Amcis partner to deliver ADC development and manufacturing platform

Mycenax and Spera forge alliance to streamline ADC drug substance

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY

Syngene International posts Q4 FY25 consolidated profit at Rs. 183.3 Cr

Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time

Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences

Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025

Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr

Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin